Emergent Biosolutions (NYSE:EBS) was downgraded by ValuEngine from a "hold" rating to a "sell" rating in a research note issued on Wednesday, ValuEngine reports.
Several other brokerages also recently commented on EBS. Cantor Fitzgerald upped their price target on shares of Emergent Biosolutions from $85.00 to $110.00 and gave the company an "overweight" rating in a report on Friday, July 17th. Guggenheim cut their price target on shares of Emergent Biosolutions from $101.00 to $87.00 and set a "buy" rating on the stock in a report on Monday, June 8th. JPMorgan Chase & Co. began coverage on shares of Emergent Biosolutions in a report on Monday. They set a "neutral" rating on the stock. Chardan Capital upped their price target on shares of Emergent Biosolutions from $86.00 to $112.00 and gave the company a "buy" rating in a report on Friday, July 31st. Finally, Wells Fargo & Company upped their price target on shares of Emergent Biosolutions from $85.00 to $93.00 and gave the company an "overweight" rating in a report on Thursday, July 2nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. Emergent Biosolutions currently has an average rating of "Hold" and a consensus target price of $92.57.
Shares of Emergent Biosolutions stock traded down $0.42 during trading hours on Wednesday, reaching $102.34. The company's stock had a trading volume of 437,564 shares, compared to its average volume of 657,756. The firm has a 50 day moving average price of $115.26 and a 200-day moving average price of $83.91. Emergent Biosolutions has a one year low of $46.37 and a one year high of $137.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.71 and a quick ratio of 1.91. The stock has a market cap of $5.42 billion, a P/E ratio of 31.88 and a beta of 1.42.
Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.53 by $1.45. Emergent Biosolutions had a net margin of 13.52% and a return on equity of 22.92%. The firm had revenue of $394.70 million for the quarter. As a group, sell-side analysts forecast that Emergent Biosolutions will post 6.67 EPS for the current fiscal year.
In related news, Director Zsolt Harsanyi sold 6,609 shares of the business's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $133.71, for a total value of $883,689.39. Following the completion of the transaction, the director now owns 24,579 shares of the company's stock, valued at $3,286,458.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Fuad El-Hibri sold 40,000 shares of the business's stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $102.73, for a total transaction of $4,109,200.00. Following the completion of the transaction, the insider now directly owns 1,209,523 shares of the company's stock, valued at approximately $124,254,297.79. The disclosure for this sale can be found here. Insiders sold 81,027 shares of company stock valued at $8,898,199 in the last quarter. 14.10% of the stock is owned by company insiders.
Large investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. increased its position in shares of Emergent Biosolutions by 3.4% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,101 shares of the biopharmaceutical company's stock valued at $237,000 after acquiring an additional 134 shares during the period. Chatham Capital Group Inc. lifted its position in Emergent Biosolutions by 0.5% during the 2nd quarter. Chatham Capital Group Inc. now owns 26,277 shares of the biopharmaceutical company's stock worth $2,078,000 after acquiring an additional 134 shares during the period. M&T Bank Corp lifted its position in Emergent Biosolutions by 0.9% during the 1st quarter. M&T Bank Corp now owns 23,921 shares of the biopharmaceutical company's stock worth $1,384,000 after acquiring an additional 208 shares during the period. Rockefeller Capital Management L.P. lifted its position in Emergent Biosolutions by 112.7% during the 1st quarter. Rockefeller Capital Management L.P. now owns 453 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 240 shares during the period. Finally, Huntington National Bank lifted its position in Emergent Biosolutions by 22.8% during the 2nd quarter. Huntington National Bank now owns 1,307 shares of the biopharmaceutical company's stock worth $103,000 after acquiring an additional 243 shares during the period.
About Emergent Biosolutions
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.
See Also: Understanding the two types of arbitrage
To view ValuEngine's full report, visit ValuEngine's official website.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
8 Consumer Staples Stocks That Offer Good Value
Chances are you’ve been spending more time at home than usual. You may also be spending more of your budget on some creature comforts that might normally make it on your shopping list. These are the consumer staples that you rely on every day.
And that’s what makes the consumer staples one of the most interesting sectors for investors.
For starters, consumer staples are defensive stocks. They are stocks that tend to perform well when the economy is doing well or when it is performing poorly. That’s because they are essentials like toilet paper, packaged foods and beverages, even alcohol and tobacco.
Now the opposite side of this coin is that the price you pay for these items is somewhat fixed. And that means these stocks don’t fit the definition of growth stocks. But the Covid-19 pandemic has changed that equation a little bit. It’s not that people are necessarily paying more for these items. But they are buying more of these items.
And this means that consumer staples are having their moment in the sun. However, it also means that right now there are several consumer staples that are looking a little pricey. But if you know anything about these stocks, you know that many of these companies are mature companies that pay a respectable, and safe, dividend.
Fortunately, there are still several stocks that appear to have room to grow and offer a nice dividend for investors.
View the "8 Consumer Staples Stocks That Offer Good Value".